live in the
 present,
not the pain

If inflammatory back pain is holding you back, it's time to move forward.

Introducing CIMZIA, the first and only FDA-approved therapy for active non-radiographic axial spondyloarthritis (nr-axSpA) with measures of inflammation.

In a clinical trial, nearly 5 out of 10 people taking CIMZIA had major improvement in disease activity within 52 weeks—for some in as fast as 2 weeks.*

*47% of CIMZIA patients at 52 weeks vs. 7% of placebo patients; 21% of CIMZIA patients at 2 weeks vs. 1% of placebo patients.

nr-axSpA How CIMZIA® (certolizumab pegol) Could Work For You

Your Back Pain Is Different – Your Treatment Should Be Too

Ask your doctor about how CIMZIA treats the signs and symptoms of nr-axSpA.

It's time to get back to life, with fewer interruptions from the inflammatory back pain of nr-axSpA. It's time to learn about CIMZIA.

CIMZIA's doctor discussion guide is available for download to assist with your next conversation with your rheumatologist

How Disruptive Is Your Inflammatory Back Pain?

Let's take a look at how you're managing your symptoms. Whether or not evidence is present on x-ray, you may still be experiencing ongoing symptoms of inflammation caused by non-radiographic axial spondyloarthritis. Having an honest conversation with a rheumatologist about its impact may help uncover the right diagnosis for you.

Want important reminders and quick tips from CIMZIA?

Just check your inbox.